skip to main content
Guest
e-Shelf
My Account
Sign out
Sign in
This feature requires javascript
Tags
e-Journals
e-Books
Databases
USP Libraries
Help
Help
Language:
English
Spanish
Portuguese (Brazil)
This feature required javascript
This feature requires javascript
Primo Search
General Search
General Search
Physical Collection
Physical Collections
USP Intelectual Production
USP Production
Search For:
Clear Search Box
Search in:
General Search
Or hit Enter to replace search target
Or select another collection:
Search in:
General Search
Advanced Search
Browse Search
This feature requires javascript
This feature requires javascript
Modulation of oncogenic potential by alternative gene use in human prostate cancer
Pasternack, Gary R ; Kadkol, Shrihari S ; Brody, Jonathan R ;
Pevsner
, Jonathan ; Bai, Jining
Nature medicine, 1999-03, Vol.5 (3), p.275-279
[Peer Reviewed Journal]
United States
Full text available
Citations
Cited by
View Online
Details
Reviews & Tags
More
Times Cited
This feature requires javascript
Actions
Add to e-Shelf
Remove from e-Shelf
E-mail
Print
Permalink
Citation
EasyBib
EndNote
RefWorks
Delicious
Export RIS
Export BibTeX
This feature requires javascript
Title:
Modulation of oncogenic potential by alternative gene use in human prostate cancer
Author:
Pasternack, Gary R
;
Kadkol, Shrihari S
;
Brody, Jonathan R
;
Pevsner
, Jonathan
;
Bai, Jining
Subjects:
Alternative Splicing
;
Humans
;
Male
;
Nuclear Proteins - genetics
;
Phosphoproteins - genetics
;
Prostatic Hyperplasia - genetics
;
Prostatic Neoplasms - genetics
;
RNA, Messenger
Is Part Of:
Nature medicine, 1999-03, Vol.5 (3), p.275-279
Notes:
ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 23
ObjectType-Article-1
ObjectType-Feature-2
Description:
Only a small percentage of primary prostate cancers have genetic changes. In contrast, nearly 90% of clinically significant human prostate cancers seems to express high levels of the nuclear phosphoprotein pp32 by in situ hybridization. Because pp32 inhibits oncogene-mediated transformation, we investigated its paradoxical expression in cancer by comparing the sequence and function of pp32 species from paired benign prostate tissue and adjacent prostatic carcinoma from three patients. Here we demonstrate that pp32 is expressed in benign prostatic tissue, but pp32r1 and pp32r2, closely-related genes located on different chromosomes, are expressed in prostate cancer. Although pp32 is a tumor suppressor, pp32r1 and pp32r2 are tumorigenic. Alternative use of the pp32, pp32r1 and pp32r2 genes may modulate the oncogenic potential of human prostate cancer.
Publisher:
United States
Language:
English
Links
View this record in MEDLINE/PubMed
This feature requires javascript
This feature requires javascript
Back to results list
Previous
Result
4
Next
This feature requires javascript
This feature requires javascript
Searching Remote Databases, Please Wait
Searching for
in
scope:(USP_VIDEOS),scope:("PRIMO"),scope:(USP_FISICO),scope:(USP_EREVISTAS),scope:(USP),scope:(USP_EBOOKS),scope:(USP_PRODUCAO),primo_central_multiple_fe
Show me what you have so far
This feature requires javascript
This feature requires javascript